ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

ClinicalTrials.gov ID: NCT04154956

Public ClinicalTrials.gov record NCT04154956. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors

Study identification

NCT ID
NCT04154956
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
389 participants

Conditions and interventions

Interventions

  • Docetaxel Drug
  • SAR408701 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 5, 2020
Primary completion
Sep 21, 2023
Completion
Mar 30, 2026
Last update posted
Aug 4, 2025

2020 – 2026

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
8
Facility City State ZIP Site status
Florida Cancer Specialists South Division- Site Number : 8400020 Fort Myers Florida 33901
Florida Cancer Specialists North Division- Site Number : 8400019 St. Petersburg Florida 33705
Ca & Hem Center Of W Michigan- Site Number : 8400016 Grand Rapids Michigan 49546
Roswell Park Cancer Institute Site Number : 8400011 Buffalo New York 14263-0001
Lankenau Hospital Cancer Center- Site Number : 8400017 Wynnewood Pennsylvania 19096-3411
Renovatio Clinical- Site Number : 8400032 El Paso Texas 79915
Renovatio Clinical - Site Number : 8400013 The Woodlands Texas 77380
Medical College of Wisconsin- Site Number : 8400006 Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 161 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04154956, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 4, 2025 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04154956 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →